STOCK TITAN
  1. Home
  2. News
  3. MIST

Milestone Pharmaceuticals Inc. Common Shares - MIST STOCK NEWS

Welcome to our dedicated page for Milestone Pharmaceuticals Common Shares news (Ticker: MIST), a resource for investors and traders seeking the latest updates and insights on Milestone Pharmaceuticals Common Shares stock.

Milestone Pharmaceuticals Inc. (Symbol: MIST) is a biopharmaceutical company headquartered at 6100 Royalmount Ave, Montreal, QC, Canada. The company specializes in developing and commercializing innovative treatments for cardiovascular conditions, with a key focus on its lead investigational product, etripamil.

Milestone's primary product, etripamil, is a calcium channel blocker designed for rapid onset as a nasal spray. This unique formulation allows patients to self-administer the medication to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). PSVT is a condition characterized by an abnormally fast heart rate, which can be both sudden and recurrent.

The company is also conducting a Phase 2 clinical trial to evaluate the efficacy of etripamil for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR). This trial marks another significant step in expanding the usage of etripamil to address additional cardiovascular indications.

Recent Achievements and Current Projects:

  • Milestone intends to use the proceeds from its latest offering to further the development of etripamil for PSVT and AFib-RVR, along with other general corporate purposes.
  • The company has secured a shelf registration statement on Form S-3, effective as of February 2, 2022, allowing for streamlined securities offering.
  • Milestone actively participates in educational initiatives, such as partnering with the Arrhythmia Alliance for SVT Awareness Day, aimed at raising awareness about heart rhythm disorders.

Financial Condition and Partnerships: Milestone maintains a strong financial position, supported by recent offerings and strategic partnerships. The company's collaborations with healthcare organizations and participation in global awareness campaigns underline its commitment to improving cardiovascular health.

Key Highlights:

  • Innovative treatment for PSVT with a patient-administered nasal spray.
  • Ongoing Phase 2 trial for AFib-RVR.
  • Effective use of proceeds for development and expansion.
  • Active involvement in cardiovascular health awareness initiatives.

With a robust pipeline and strategic initiatives, Milestone Pharmaceuticals Inc. is dedicated to addressing unmet needs in cardiovascular care, making significant strides in the biopharmaceutical industry.

News

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Rhea-AI Summary
Milestone Pharmaceuticals Inc. (MIST) will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference on March 5, 2024. The webcast will be available live and on replay for 90 days on Milestone's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
conferences
-
News

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Rhea-AI Summary
Milestone Pharmaceuticals Inc. announces the pricing of its underwritten public offering, expecting to raise around $30.0 million through the sale of common shares and pre-funded warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.13%
Tags
offering
-
News

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Rhea-AI Summary
Milestone Pharmaceuticals Inc. (MIST) announces the commencement of an underwritten public offering of common shares and pre-funded warrants to certain investors. The company aims to use the net proceeds for the development of etripamil in cardiovascular indications and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.13%
Tags
offering
News

Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT

Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) plans to resubmit the NDA for etripamil to the FDA for PSVT treatment following a Refusal to File letter. The company will restructure data sets and reformat files based on FDA guidance. No additional clinical trials are required. Cash conservation measures will fund operations until mid-2025, with potential $75 million payment upon FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.12%
Tags
none
-
News

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.9%
Tags
none
-
News

Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

Rhea-AI Summary
Milestone Pharmaceuticals Inc. (MIST) to Participate in Fireside Chat at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.16%
Tags
conferences
News

Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) submits New Drug Application for CARDAMYST™ nasal spray to treat PSVT and reports positive Phase 2 data for etripamil in AFib-RVR. The company plans to host an Investor and Analyst Webcast to review the ReVeRA Phase 2 study results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.59%
Tags
earnings
-
News

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced positive Phase 2 data for etripamil nasal spray, showing a statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate compared to placebo. The results support further clinical development in a Phase 3 trial for the management of AFib-RVR. Safety and tolerability data were generally consistent with previous studies, indicating potential for self-administered etripamil for AFib-RVR treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR

Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) will host a virtual investor and analyst webcast on November 13, 2023, focusing on the results from the ReVeRA Phase 2 study of investigational new drug etripamil in patients with atrial fibrillation with rapid ventricular rate. Key opinion leaders, including A. John Camm, MD, and Sean Pokorney, MD, will join the webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.39%
Tags
conferences clinical trial
News

Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Rhea-AI Summary
Milestone Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for etripamil nasal spray to treat PSVT. The company believes etripamil is twice as effective and three times as fast as a placebo in restoring normal heart rhythm. If approved, it will be the first rapid and reliable option for treating serious heart arrhythmias.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
none

FAQ

What is the current stock price of Milestone Pharmaceuticals Common Shares (MIST)?

The current stock price of Milestone Pharmaceuticals Common Shares (MIST) is $1.479 as of November 4, 2024.

What is the market cap of Milestone Pharmaceuticals Common Shares (MIST)?

The market cap of Milestone Pharmaceuticals Common Shares (MIST) is approximately 78.8M.

What does Milestone Pharmaceuticals Inc. specialize in?

Milestone Pharmaceuticals Inc. specializes in developing and commercializing innovative treatments for cardiovascular conditions, particularly focusing on the investigational product etripamil.

What is etripamil?

Etripamil is a rapid-onset nasal spray calcium channel blocker developed to self-administer by patients to terminate episodes of paroxysmal supraventricular tachycardia (PSVT).

What is PSVT?

Paroxysmal supraventricular tachycardia (PSVT) is a condition characterized by a sudden and recurrent fast heart rate, which etripamil aims to treat effectively.

What are Milestone's recent achievements?

Recent achievements include a Phase 2 clinical trial for AFib-RVR, a successful securities offering, and active participation in SVT awareness initiatives.

How is Milestone Pharmaceuticals funded?

Milestone Pharmaceuticals utilizes proceeds from securities offerings to fund the development of its products and for general corporate purposes.

What is the significance of Milestone's partnership with Arrhythmia Alliance?

The partnership aims to raise awareness about arrhythmias and educate the public on conditions like SVT through initiatives like SVT Awareness Day.

Where is Milestone Pharmaceuticals located?

The company is headquartered at 6100 Royalmount Ave, Montreal, QC, Canada.

What are the future plans for etripamil?

Future plans include continued development for its primary indication PSVT and expanding its use to treat AFib-RVR, currently under a Phase 2 clinical trial.

How can I obtain the latest financial reports for Milestone?

Latest financial reports and other filings can be accessed on the U.S. Securities and Exchange Commission's website or by contacting Milestone's investor relations.

What are the risks associated with Milestone's forward-looking statements?

These risks include regulatory approval uncertainties, clinical trial complexities, economic conditions, and sufficiency of capital resources, as detailed in Milestone's SEC filings.

Stock MIST logo
Milestone Pharmaceuticals Inc. Common Shares

Nasdaq:MIST

MIST Rankings

#4550 Ranked by Market Cap
N/A Ranked by Dividends

MIST Stock Data

78.84M
53.27M
0.69%
56.94%
0.84%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MONTREAL